Alcohol-attributable cancer deaths in the U.S. doubled from about 11,400 in 1990 to more than 23,100 in 2023. Study found alcohol's impact extends far beyond liver cancer, with growing burdens from colorectal, breast, esophageal, pancreatic and other cancers.

Huntsman Cancer Institute marks a major construction milestone for its Vineyard campus that will bring hope and healing closer to patients and families in Utah County and the Mountain West.

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.

A newly funded study at the University of Oklahoma aims to increase prostate-specific antigen (PSA) screening among Black men in Oklahoma, who die from prostate cancer at rates two to four times higher than other racial groups. An interactive app called Connect2Care may hold the key to early detection, which is crucial for improving survival.

Researchers at the Indian Institute of Technology Gandhinagar (IITGN) have developed an ER-targeted gold nanorod platform that combines anticancer drug delivery with photothermal therapy. Featuring the first reported integration of gold nanorods with cisplatin and indomethacin for ER-targeted cancer treatment, the platform triggered ER stress, autophagy and apoptosis, and reduced the viability of colon, cervical and breast cancer cells while showing negligible toxicity towards tested non-cancerous cells. The approach offers a promising direction for developing more precise cancer therapies, although further studies are needed for clinical translation.

KRAS inhibitors shrank existing NF1-related nerve tumors and prevented new tumors from forming in a mouse model that closely mirrors the human disease, according to new research led by experts at Cincinnati Children's.

Researchers have demonstrated a label-free imaging technique that can identify immune cell subtypes and detect early immune activation within blood samples by measuring the natural fluorescence of metabolic molecules inside cells. Using optical metabolic imaging, the team analyzed thousands of peripheral blood mononuclear cells from healthy donors and showed that the method could distinguish activated from resting cells with 94% accuracy just two hours after stimulation, while also identifying monocytes and natural killer cells within mixed cell populations. The approach provides a nondestructive way to measure cellular metabolism at single-cell resolution, offering insights into immune-cell function and heterogeneity that are not captured by conventional surface-marker methods. The researchers say the technique could eventually support disease monitoring, drug development, and the production of cell therapies by providing rapid metabolic profiling of immune cells.